Post-pandemic recovery and demand surge are set to influence the Surgical Site Infection Control market, taking it from USD 5.15 billion in 2023 to an anticipated USD 6.21 billion by 2028. Projected growth is at a Compound Annual Growth Rate (CAGR) of about 3.80% over this five-year period. COVID-19, which dictated forced halts on elective surgery due to defensive healthcare policies, had induced a global decline in surgical procedures.
For example, the study unveiled in October 2021 by the National Library of Medicine marked a 42.8% drop in global general surgery admissions. This undesirable shift had a profound impact on the Surgical Site Infection Control Market. However, the pandemic emphasized the pivotal role of traditional infection control methods, paramount among them hand hygiene.
As health conditions begin to normalize with recoveries and resumed elective surgeries, the market bounces back to its pre-pandemic vigor. In March of 2022, PDI introduced new disinfectant products – Sani-24 Germicidal Disposable Wipe, Sani-HyPerCide Germicidal Disposable Wipe, and Sani-HyPerCide Germicidal Spray – to assist infection prevention professionals counter the surge of healthcare-associated infections (HAIs) and the ongoing COVID-19 challenge.
The escalating rate of hospital-acquired infections due to the cumulative surgical operations and the expanding geriatric population contributes to the expected market rally. Surgical Site Infection (SSI), marked as the most prevalent post-surgical healthcare-associated infection, carries severe implications such as morbidity, mortality, ICU transfers, extended hospital stays, and readmissions. F
actoring the impact of the rising global geriatric population, the United Nations’ World Ageing Population 2022 point that by 2050, 16% of the global population will be aged 65 years and above, complementary to the noted increase in the incidence of chronic diseases, it is clear that older individuals present an increased demand for surgical measures. This development will likely push the growth of the Surgical Site Infection Control sector.
The rise in organ transplants, as evidenced by the 40,000 procedures performed in the U.S in 2021, and technological advancements, such as TELA Bio’s March 2022 launch of SiteGuard – an antimicrobial solution that tackles biofilms resisting traditional methods, all fuel this sector’s growth. However, obstacles like the lack of SSI awareness among individuals pose challenges to this upward market trajectory. This detailed piece also provides an in-depth review of market trends and the specific contribution of the superficial incisional segment to the sector’s growth. Moreover, it sheds light on the market leader North America’s role and the impact of innovations on the market landscape.
Source: https://finance.yahoo.com/news/surgical-infection-control-market-size-153000594.html